S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Catalyst Pharmaceuticals, Inc. (CPRX)
Chart Events
Performance Outlook
| Previous Close | 6.92 |
| Open | 6.94 |
| Bid | 6.75 x 4000 |
| Ask | 7.17 x 2200 |
| Day's Range | 6.78 - 7.17 |
| 52 Week Range | 4.81 - 8.65 |
| Volume | |
| Avg. Volume | 1,178,401 |
| Market Cap | 728.013M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | 18.15 |
| EPS (TTM) | 0.39 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- GlobeNewswire
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences. The management team will also host one-on-one investor meetings
- Simply Wall St.
Catalyst Pharmaceuticals (NASDAQ:CPRX) pulls back 10% this week, but still delivers shareholders solid 27% CAGR over 5 years
Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders might be concerned after seeing the share price drop 14% in...
- Zacks
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
